Curadel Pharma is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Its novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues. Curadel’s lead candidate, CPI-003, represents a potential best-in-class zwitterionic targeted alpha therapy (TAT) initially focused on the treatment of challenging rare cancers. The company is also developing image-guided surgical drugs. Its late-stage drug for ureter imaging is currently under evaluation in a pivotal trial. Curadel was founded by zwitterionicity pioneer John V. Frangioni, M.D., Ph.D., Professor of Medicine (Emeritus) and Professor of Radiology (Emeritus) at Harvard Medical School.
Company Details
- Employees
- 27
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.curadel.com
Curadel Pharma Questions
Curadel Pharma's website is http://www.curadel.com
Curadel Pharma's LinkedIn profile is https://www.linkedin.com/company/curadelpharma
Curadel Pharma has
27 employees.
View email and phone details for 27
employees at Curadel Pharma.
Curadel Pharma's industry is
Biotechnology Research
Curadel Pharma's top competitors are
Orna Therapeutics,
Merck Healthcare,
Ipsen,
Pfizer,
Chiltern,
Thermo Fisher Scientific,
Somewhere,
Bruntwork,
Discover International,
Syner-G Biopharma Group.
Curadel Pharma's categories are Biotechnology Research
Curadel Pharma's founding year is 2012
